|
|||||
|
|
Identification of acrolein-conjugated protein in plasma of patients with brain infarction |
|
| Authors: | Madoka Yoshida Kyohei Higashi Lihua Jin Takehiro Suzuki Naoshi Dohmae Yutaka Tamura Toshihiko Toida Keiko Kashiwagi |
| Affiliation: | a Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan b Amine Pharma Research Institute, Innovation Plaza at Chiba University, 1-8-15 Inohana, Chuo-ku, Chiba 260-0856, Japan c Biomolecular Characterization Team, RIKEN Advanced Science Institute and CREST, JST, 2-1 Hirosawa, Wako 351-0198, Japan d Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan e Faculty of Pharmacy, Chiba Institute of Science, 15-8 Shiomi-cho, Choshi, Chiba 288-0025, Japan |
| Abstract: | It is known that the level of protein-conjugated acrolein in plasma is a good marker of chronic renal failure and brain infarction. Thus, studies were carried out to determine which kinds of plasma proteins are conjugated with acrolein. It was found that acrolein was mainly conjugated with albumin. Tandem mass spectrometry analysis demonstrated that Lys-557 and Lys-560, located at the surface of domain III of albumin, were the major sites conjugated with acrolein. This is the first report to identify the amino acid residues in a protein modified by acrolein in vivo. It was found that conjugation of acrolein with albumin contributed to a decrease in the toxicity of acrolein. |
| Keywords: | Acrolein Albumin MP-lysine LC-MS/MS Brain infarction Renal failure |
| 本文献已被 ScienceDirect 等数据库收录！ | |